Ruti Aga's Six-Year Ban: How a Forged Prescription Destroyed a Defensible Case

The clinic named on the prescription did not exist. The "doctor" who signed it was a family member with no medical registration. Asked where the prescription pad had come from, the answer was: left over from a former workplace. In the Athletics Integrity Unit's investigation, that paper trail collapsed at three independent points, and each collapse added weight to the sanction. Ruti Aga, the 32-year-old Ethiopian marathoner, was banned for six years in total — two for methylprednisolone, four for submitting a fabricated document to justify it. That is the arithmetic in the AIU statement issued on Thursday. The ban runs from 10 September, the same date her provisional suspension began. Her record needs to be laid out first, because in this case the record is the part that survives. She won the 2026 Tokyo Marathon in 2:20:40, a Major title in a field crowded with Ethiopian and Kenyan depth. She was second in Berlin in 2026 in 2:18:34. Three second-place finishes at World Marathon Majors. A runner between 2:18 and 2:20 sits in the global elite, but inside Ethiopia she is not the fastest — she is one of many fast. I watched that 2026 Tokyo race on screen, and the clearest thing about her that morning was that her strength sat in the last ten kilometres, not the first five. Hold on to that detail, because when a comeback is discussed six years from now, the age curve being invoked will apply to precisely that capacity. In March she won a half marathon in China, and an in-competition sample from that race returned methylprednisolone. The race is unnamed in the source. Her time is not given. The field's depth is not given. The scope of disqualification is not stated. What exists is the AIU statement and her explanation that the substance was for a knee injury. No conclusion about form can be drawn from incomplete information: "she won" tells us only that the field was strong enough and the race tier high enough to carry in-competition testing, most likely a World Athletics Label road race. A half marathon carries no Olympic qualifying function, so selection arithmetic is not implicated. What is implicated is the appearance fee and the result, both now at risk. Now the pharmacology, because the case turns there. Methylprednisolone is not an anabolic steroid. It is a glucocorticoid, class S9 on the WADA Prohibited List, and that class is prohibited in-competition only, by injection, oral or rectal route. The distinction vanished in much of the reporting, which labelled it a "prohibited steroid." The distinction is not small. An anabolic-steroid allegation goes straight to intent; a glucocorticoid allegation goes straight to timing and route. In road racing the in-competition testing window opens at 23:59 the night before the race. An injection into the knee three or four days earlier can still be present when the sample is collected. Treating an injury is not an offence; leaving residues in-competition is. Aga therefore had a real defence available: route, timing and medical necessity, documented. A Therapeutic Use Exemption was an open path, and so was scheduling the treatment far enough out that nothing remained. The substance has no proven endurance benefit in any case — it reduces pain and swelling, it does not raise oxygen capacity. The forged prescription destroyed that defence. The arithmetic is the clearest way to see it: two years for presence, four for tampering. Four years is the Code's standard tampering sanction, which tells us the panel treated the tampering as fully culpable. The two-year presence sanction tells us the violation was found proven but was not taken to the no-fault or no-significant-fault end. With genuine medical records, that end was open, and the tampering charge would never have existed. This is a case about paper, not about a drug, and that changes the direction of the reporting. China's half marathon circuit is an attractive income tier for East African marathoners between Majors: large appearance fees, low risk, few races. The economic model for a 2:18–2:20 runner rests on it — a few Majors a year, Asian label races in between. That same tier is now the AIU's highest-yield testing ground. Money and testing are colliding in the same races, and that is the new risk profile of this race category. Medical support is the least-written part of the structure. The "doctor" treating the knee was a family member without registration. No team physiotherapist, no registered team physician appears anywhere. A properly managed athlete either holds a TUE or schedules the injection far enough from competition that nothing remains; neither happened here. The most telling fact is that the tampering charge also rested on statements made in interview — not on the document alone. The structure of women's road racing matters here. Compared with male runners, women marathoners sit on a thinner layer of appearance fees and sponsorship, and the pressure to mask injury is greater, because skipping a race is not just skipping a race — it is the next fee negotiation. Chronic knee trouble plus cheap injections is a pairing produced by that pressure. This is not the moral character of one athlete; it is a structure, and structures are always charged to whoever has the least defence. Here is the part reporting keeps getting wrong. A six-year ban bears no relation to a substance with no proven endurance benefit. What the weight of the sanction matches is the document and the statement. The real protagonist of this story is the prescription. It reads backwards because public argument stops at the word "steroid," and behind that word the three conditions — class, route, timing — disappear. A media error simplifies a case, and every subsequent comparison is degraded by that simplification. The uncomfortable truth is that the athlete had a defence and dismantled it herself. "Forge the paper" is less the foolishness of one runner than the habit of a network that fears the TUE paperwork and reaches for the immediate fix. That deficit of medical literacy is converted into a sanction, while the people who created the deficit — agent, manager, the unregistered practitioner — do not appear anywhere in the sanction table. The AIU statement names only the family member. Whether anyone who advised on or accepted the document was investigated is not publicly clear. The real meaning of the ban shows up in career arithmetic. Age 32, six years from 10 September — a return at roughly 38. Ethiopia's women's marathon depth holds an entire generation running under 2:16. A 38-year-old with a doping record gives a national selection committee no reason to pick her, and demanding that she "prove herself" at that age is meaningless — it adds psychological load and re-injury risk and changes nothing. In practice, this ban is the end of a career. The 2026 Tokyo title does not fall automatically with this decision. The violation is anchored to that March race; earlier results are annulled only on a finding of earlier use. The source does not state the disqualification scope, and that should not be left to the reader's assumption. What is clear is the separation: the podium ledger and the integrity ledger are two different accounts, and in this case they must be kept apart. Merging one into the other is the reliable way to misread both. What to watch next. An appeal window is open — typically about 21 days from the reasoned decision — but a document-based finding is hard to overturn, so the risk is low and so is the upside. What can change is procedure, not rule. World Athletics Label road races should require a registered team physician's name on the entry form; that single line would show which runner has real medical support behind her and which has none. Agent and management contracts should carry TUE literacy as a term, not only fee negotiation. And the AIU should publish annually how many tampering charges arise in which region and which race tier — then we would know whether this is the story of one runner or of a system. The day a knee injection given three days before a race becomes a date filled into a form rather than a doping case, the need to forge these prescriptions will end on its own. The question is not whether the sanction was harsh or lenient. The question is why, for a runner at that level, the route through real paperwork looked longer than the route through fake paperwork.